201 related articles for article (PubMed ID: 29061769)
1. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.
Berger M; VON Schweinitz D
Anticancer Res; 2017 Nov; 37(11):5911-5918. PubMed ID: 29061769
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Innovations for Targeting Hepatoblastoma.
Garnier A; Ilmer M; Kappler R; Berger M
Anticancer Res; 2016 Nov; 36(11):5577-5592. PubMed ID: 27793881
[TBL] [Abstract][Full Text] [Related]
3. Targeting tachykinin receptors in neuroblastoma.
Henssen AG; Odersky A; Szymansky A; Seiler M; Althoff K; Beckers A; Speleman F; Schäfers S; De Preter K; Astrahanseff K; Struck J; Schramm A; Eggert A; Bergmann A; Schulte JH
Oncotarget; 2017 Jan; 8(1):430-443. PubMed ID: 27888795
[TBL] [Abstract][Full Text] [Related]
4. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
[TBL] [Abstract][Full Text] [Related]
5. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
6. Current management of neuroblastoma and future direction.
Pastor ER; Mousa SA
Crit Rev Oncol Hematol; 2019 Jun; 138():38-43. PubMed ID: 31092383
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of neuroblastoma.
George RE; Diller L; Bernstein ML
Expert Opin Pharmacother; 2010 Jun; 11(9):1467-78. PubMed ID: 20408767
[TBL] [Abstract][Full Text] [Related]
8. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
9. Development of a Ligand-Targeted Therapeutic Agent for Neurokinin-1 Receptor Expressing Cancers.
Kanduluru AK; Low PS
Mol Pharm; 2017 Nov; 14(11):3859-3865. PubMed ID: 28969417
[TBL] [Abstract][Full Text] [Related]
10. Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy.
Cordier D; Gerber A; Kluba C; Bauman A; Hutter G; Mindt TL; Mariani L
Cancer Biother Radiopharm; 2014 Jun; 29(5):221-6. PubMed ID: 24552486
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of neuroblastoma: present, past and future.
Raffaghello L; Pistoia V
Expert Rev Neurother; 2006 Apr; 6(4):509-18. PubMed ID: 16623650
[TBL] [Abstract][Full Text] [Related]
12. Immunocombination therapy for high-risk neuroblastoma.
Kroesen M; Lindau D; Hoogerbrugge P; Adema GJ
Immunotherapy; 2012 Feb; 4(2):163-74. PubMed ID: 22394368
[TBL] [Abstract][Full Text] [Related]
13. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.
Zage PE; Louis CU; Cohn SL
Pediatr Blood Cancer; 2012 Jul; 58(7):1099-105. PubMed ID: 22378620
[TBL] [Abstract][Full Text] [Related]
14. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].
Rousseau R; Combaret V; Yvon E; Schell M; Philip I; Puisieux A; Frappaz D; Philip T; Bergeron C
Bull Cancer; 2006 Feb; 93(2):153-61. PubMed ID: 16517413
[TBL] [Abstract][Full Text] [Related]
16. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
Gustafson WC; Matthay KK
Expert Rev Neurother; 2011 Oct; 11(10):1411-23. PubMed ID: 21955198
[TBL] [Abstract][Full Text] [Related]
17. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic targets for the treatment of high-risk neuroblastoma.
Wagner LM; Danks MK
J Cell Biochem; 2009 May; 107(1):46-57. PubMed ID: 19277986
[TBL] [Abstract][Full Text] [Related]
19. [Rational bases for new approaches to the therapy of pediatric solid tumors: immunotherapy and gene therapy].
Pistoia V; Prigione I; Facchetti P; Corrias MV
Pediatr Med Chir; 1994; 16(3):219-25. PubMed ID: 7971443
[TBL] [Abstract][Full Text] [Related]
20. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
